DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

Phase 2

DPX-Survivac & PembrolizumabDPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sponsor:

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Code:

NCT04920617

Conditions

Relapsed Diffuse Large B-cell Lymphoma

Refractory Diffuse Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

DPX-Survivac

Pembrolizumab

CPA

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by ImmunoVaccine Technologies, Inc. (IMV Inc.) on 2023-04-07.